Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis in susceptible bacteria.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Treatment of serious infections caused by susceptible gram-negative bacteria,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burns,Off-label: Bacterial endocarditis prophylaxis,Off-label: Intraocular injection for endophthalmitis
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
1-2 mg/kg IV every 8 hours, adjusted based on serum concentrations and creatinine clearance.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged to 24-48 hours in anuric patients requiring dose adjustment.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Gentamicin is not significantly metabolized; it is excreted primarily unchanged by glomerular filtration.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: >90% unchanged via glomerular filtration; biliary: <2%; fecal: negligible.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
<30% bound primarily to albumin; low binding reduces displacement interactions.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.2-0.3 L/kg; approximates extracellular fluid volume; increased in edema, ascites, or burns.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intramuscular: ~100%; topical: minimal systemic absorption (<1%); intravenous: 100% (by definition).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Cr Cl 60-90 m L/min: 1.7 mg/kg every 12 hours; Cr Cl 40-59 m L/min: 1.7 mg/kg every 24 hours; Cr Cl 20-39 m L/min: 1.7 mg/kg as a single dose then adjust based on serum levels; Cr Cl <20 m L/min: 1.7 mg/kg as a single dose then redose based on serum levels; Hemodialysis: 1-2 mg/kg after dialysis with supplemental dosing based on serum levels.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No dose adjustment required for hepatic impairment; gentamicin is primarily renally eliminated.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Neonates (<7 days): 4-5 mg/kg IV every 24-36 hours; Infants >7 days: 2.5 mg/kg IV every 8 hours; Children: 2-2.5 mg/kg IV every 8 hours; adjust based on serum concentrations and renal function.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Dose adjustment based on renal function; calculate Cr Cl using Cockcroft-Gault equation with ideal body weight; typical starting dose: 1-1.7 mg/kg IV every 8-12 hours, with subsequent dosing guided by serum concentrations.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
WARNING: OTOTOXICITY AND NEPHROTOXICITY. Gentamicin can cause ototoxicity (vestibular and auditory) and nephrotoxicity. Risk increases with prolonged use, high doses, renal impairment, and advanced age. Monitor renal function and auditory function regularly.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Neurotoxicity including ototoxicity and nephrotoxicity,Neuromuscular blockade leading to respiratory paralysis,Superinfection with resistant organisms,May worsen weakness in myasthenia gravis or Parkinson's disease,Use with caution in premature infants and neonates due to renal immaturity,Monitor serum drug levels to avoid toxicity
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to gentamicin or other aminoglycosides,Severe renal disease with anuria (relative contraindication; use only if benefits outweigh risks)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions. Avoid excessive potassium intake if renal impairment.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Gentamicin is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. First trimester: Avoid unless essential due to potential for ototoxicity and nephrotoxicity. Second and third trimesters: Use only for severe infections when alternative antibiotics are not available. Risk of fetal inner ear damage and renal impairment associated with aminoglycosides.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Gentamicin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.15-0.2. Oral bioavailability in infants is poor, minimizing systemic absorption. However, potential for disruption of infant gut flora and direct irritation. Use with caution, especially in neonates with immature renal function. Monitor infant for diarrhea or rash.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Increased volume of distribution and enhanced renal clearance during pregnancy may necessitate higher doses or more frequent administration to achieve therapeutic serum levels. Therapeutic drug monitoring is recommended. Initial dosing based on ideal body weight and renal function; adjust to maintain target peak (6-10 mcg/m L) and trough (<2 mcg/m L) concentrations.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Monitor peak (30 min after 30-min infusion) and trough (just before next dose) levels; target peak 5-10 mcg/m L, trough <2 mcg/m L. Adjust dose in renal impairment. Avoid concurrent ototoxic/nephrotoxic drugs. Consider once-daily dosing for synergy with beta-lactams. Assess for vestibular toxicity with Romberg test.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Report any hearing loss, ringing in ears, dizziness, or balance problems immediately.,Drink plenty of fluids unless instructed otherwise by your doctor.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.,This medication is given intravenously; do not mix with other drugs in the same line without pharmacy approval.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Gentamicin, an aminoglycoside antibiotic, and Amphotericin B, a polyene antifungal agent, both independently induce nephrotoxicity. Concurrent administration synergistically increases the risk of acute kidney injury, characterized by elevated serum creatinine, reduced glomerular filtration rate, and potential tubular necrosis. This additive nephrotoxic effect necessitates cautious use and enhanced monitoring."
"Pamidronic acid, a bisphosphonate, inhibits osteoclast-mediated bone resorption, reducing serum calcium levels. Gentamicin, an aminoglycoside antibiotic, can cause renal tubular injury, impairing the kidney's ability to reabsorb calcium and leading to hypocalcemia. Concurrent use increases the risk of severe, symptomatic hypocalcemia, potentially manifesting as tetany, arrhythmias, or seizures."
"Gentamicin and foscarnet both have nephrotoxic potential, and concurrent use can lead to additive or synergistic renal injury. This interaction increases the risk of acute kidney injury, particularly in patients with pre-existing renal impairment or volume depletion, and may result in reduced glomerular filtration rate and elevated serum creatinine."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis in susceptible bacteria.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 1-2 mg/kg IV every 8 hours, adjusted based on serum concentrations and creatinine clearance.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Gentamicin is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.